통합 머신러닝으로 간세포암 MYBL2를 새로운 예후·치료 표적으로 확인
고통받는 간세포암, 새로운 지표가 필요해요
간세포암(HCC)은 진단·예후·치료가 모두 어려워 환자와 가족에게 큰 고통을 안겨줘요. 기존 바이오마커가 충분히 정확하지 않아 치료 선택이 불확실했죠.
AI와 실험이 만나 MYBL2를 밝혀냈어요
우리는 LASSO(Least Absolute Shrinkage and Selection Operator) 기반 머신러닝을 TCGA와 GEO 데이터에 적용하고, 단일세포 전사체와 CRISPR 의존성 스크리닝까지 더했어요. 그 결과 MYBL2(MYBL2)가 정상 간보다 암 조직에서 거의 완벽하게 구분(AUC 0.968)되고, 높은 발현이 고등급, 미세혈관 침윤, HBV 양성, TACE 비반응 등 나쁜 임상특성과 연결됐어요.
치료와 면역에까지 영향이 커요
MYBL2는 AFP(알파‑페토프로테인), MKI67, PCNA, BIRC5 같은 증식 마커와 강하게 상관했고, CRISPR 제거가 대부분 HCC 세포주의 성장을 억제했어요. 또한 약물 민감도 분석에서 MYBL2 고발현이 sorafenib(소라페닙) 효과와 연관돼 면역억제 환경과도 연결된다는 점을 발견했어요.
앞으로의 의미 또는 전망
이제 MYBL2를 기반으로 한 정밀 진단키트와 MYBL2를 표적으로 하는 신약 개발이 현실화될 수 있어요. 환자 맞춤 치료가 가능해지면 생존율이 크게 향상될 전망이에요.
BACKGROUND: Hepatocellular carcinoma (HCC) presents with poor treatment outcomes, creating an urgent need for novel biomarkers to improve diagnosis, prognosis, and precision medicine. While the MYB family of oncogenes is implicated in cancer, the role and regulatory mechanisms of its member, particularly MYB proto-oncogene like 2 (MYBL2), remain underexplored in HCC. Therefore, this study aimed to systematically validate the clinical significance of MYBL2, elucidate its functional role in tumor progression and drug sensitivity, and identify its upstream regulatory mechanisms using an integrative machine learning and experimental framework. METHODS: We applied an integrative pipeline combining LASSO-based feature selection on TCGA and GEO cohorts, single-cell transcriptomics, pharmacogenomic surveys, and CRISPR dependency screens. These computational approaches were complemented by RESULTS: MYBL2 robustly discriminated tumor from normal liver (AUC = 0.968), and high expression was associated with adverse features, including higher grade, microvascular invasion, HBV positivity, nonresponse to TACE, and worse survival. A nomogram combining MYBL2 with AJCC stage improved 1-, 3-, and 5-year AUCs versus stage alone. MYBL2 correlated with proliferative biomarkers (AFP, MKI67, PCNA, BIRC5) and CRISPR knockout inhibited growth in most HCC lines. High MYBL2 expression was associated with greater sensitivity to sorafenib in pharmacogenomic screens and was linked to an immunosuppressive microenvironment and higher MSI. Mechanistically, miR-29a was shown to suppress MYBL2 translation by directly binding to its 3 CONCLUSIONS: MYBL2 is a potent diagnostic and prognostic biomarker in HCC that also predicts sorafenib sensitivity. Our findings establish a clear regulatory link where MYBL2 is a direct and functionally important target of the tumor-suppressive miR-29a. This positions MYBL2 as a tractable target for miR-29a-based therapeutic strategies, warranting clinical validation f
간세포암 환자들은 정확한 예후 예측과 효과적인 치료제 선택이 어려워 생존율이 낮아요. MYBL2를 새로운 바이오마커와 치료 표적으로 활용하면 개인 맞춤 치료가 가능해져 삶의 질과 기대수명이 개선될 거예요.